Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed to deplete CD19-positive B cells and improve disease activity in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). Cabaletta has been cleared to initiate a Phase 1/2 clinical trial of CABA-201 for the treatment of 6 SLE patients with active LN, and in a separate parallel cohort, 6 patients with active SLE without renal involvement, with an initial dose that is equivalent to the dose used in the September 2022 Nature Medicine publication of a 4-1BB containing CD19-CAR T construct evaluated in patients with SLE.
Elastic Sees Q1 EPS $0.24-$0.26 Vs $0.24 Est.; Revenue $343M-$345M Vs $344.95M Est.; FY25 EPS $1.35-$1.47 Vs $1.40 Est.; Revenue $1.468B-$1.48B Vs $1.48B Est.
Financial OutlookThe Company is providing the following guidance:For the first quarter of fiscal 2025 (ending July 31, 2024):Total revenue is expected to be between $343 million and $345 million, representing 17%
